| MYELOMA MINUTE | Up To The Minute News | 10.01.2020 |
|
 |
 |
| Understanding Second and Third Waves of COVID-19 as We Head into Autumn |
| “We had all hoped COVID-19 would be behind us by now,” says IMF Chairman Dr. Brian G.M. Durie. But as cases rise in many parts of the U.S. and the world, we need to “stay vigilant.” Dr. Durie shares the latest pandemic news and six steps to strengthening your resilience. |
|
|
 |
| “Everybody Loves Raymond” Cast Reunites for a Virtual Table Read |
| Join us on Friday, October 23, 2020, at 6 p.m. PT / 9 p.m. ET for an exclusive virtual table read reviving the classic sitcom “Everybody Loves Raymond.” Actor and comedian Ray Romano returns to host and will be joined by his former fellow cast members Patricia Heaton, Brad Garrett, Monica Horan, and show creator Phil Rosenthal. While the table read will be streamed free of charge, your donations will benefit the Peter Boyle Research Fund and the Black Swan Research Initiative®. |
|
|
 |
| Register NOW for this FREE Patient & Family Webinar |
| The Patient & Family Webinar, Multiple Myeloma — New Treatments, Diversity, and Caregiver Support, will take place on Saturday, October 3, 2020, at 7 a.m. PT / 10 a.m. ET. This free two-hour webinar features a panel discussion led by IMF Chief Medical Officer Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen). Panelists include Deepu Madduri, MD of Tisch Cancer Institute/Mount Sinai Hospital; Craig Emmitt Cole, MD of Michigan State University; and Beth Faiman PhD, MSN, APRN-BC, AOCN, FAAN of Cleveland Clinic Taussig Cancer Institute. IMF President, Founder, and CEO Susie Durie and IMF Vice President of Support Groups Robin Tuohy will lead a special segment dedicated to caregiver support. |
|
|
 |
| An Expanded Access Program in the US for Melflufen in Triple-Class Refractory Mulitple Myeloma Opens |
| Today, the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, formally opens. "Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients)." |
|
|
 |
| And This Too Shall Pass…. |
| Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. Note: Bookings will be in the future based on mutual availability with you and the property owner. |
|
|
 |
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
This Week’s Question:
Should FiSH testing be done at relapse? |
|
|
| |
|
|
| |
We Thank Our Sponsors:
|
| Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology |
| We also thank individuals like you for your continued support! |
|
|
| Join the conversation at The International Myeloma Foundation |
 Facebook: /Myeloma |  Twitter @IMFMyeloma |  Instagram @IMFmyeloma
www.myeloma.org |
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
1-800-452-2873 |
We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Privacy Policy |
| View as web page |
